These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Thromboembolic disease and the steroidal content of oral contraceptives.
    Author: Swyer GI.
    Journal: Res Reprod; 1970 Jul; 2(4):1. PubMed ID: 12254979.
    Abstract:
    The following invited comments were made on the recent report issued by the United Kingdom Committe on the safety of Drugs. The calculations of the report were based on 1305 reports of thromboembolism between January 1965 and June 1969 in women using oral contraceptives. Similar calculations were applied to 183 Swedish and 122 Danish reports. Combined and sequential regimes containing the same doses and type of estrogen had the same risk. Analysis of 920 reports for the United Kingdom showed and excess of reports of fatal and nonfatal thromboembolic disease with higher estrogen dosage. This was particularly noted for 150 mcg of mestranol and 100 mcg of ethinyl estradiol. Differences in effect of progressively lower doses of mestranol were less definite. Doses of 50 mcg of ethinyl estradiol produced significantly less thromboembolic disease. Reports from Sweden and Denmark for mestranol were comparable to those of the United Kingdom. Other factors besides the dose of estrogens were considered important in the risk of thromboebolism. Different combinations of other drugs with mestranol or ethinyl estradiol produced different results. An antithromboembolic effects was suggested with an increasing combined dosage of norethisterone acetate. The justification for avoiding the highest dosage of ethinyl estradiol and mestranol is well established. Lower doses, 50 mcg of mestranol, are not clearly shown to be safer than up to 100 mcg.
    [Abstract] [Full Text] [Related] [New Search]